Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUSB | P08236 | 2/20 | 0.52 |
| ▸ | EBP | Q15125 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | GLB1 | P16278 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 3/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.41 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20002903 | 0.93 | GLB1 (0.52) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL12911942 | 0.84 | GNAO1 (0.49) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL9974273 | 0.84 | — | — | |
| SCHEMBL24261571 | 0.83 | GNAO1 (0.51) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL26511527 | 0.83 | GNAO1 (0.51) | GUSBEBPSIGMAR1GNAI3GNAO1 | |
| SCHEMBL12912123 | 0.81 | BCHE (0.51) | EBPSIGMAR1GNAI3GNAO1GNAI1 | |
| SCHEMBL9815993 | 0.79 | GNAO1 (0.56) | GNAI3GNAO1GNAI1 | |
| SCHEMBL7739926 | 0.79 | GUSB (0.48) | GUSBEBPSIGMAR1GLB1GBA1 | |
| SCHEMBL14968345 | 0.78 | EBP (0.34) | GUSBEBPSIGMAR1GLB1 | |
| SCHEMBL14968346 | 0.78 | GBA1 (0.38) | GUSBEBPSIGMAR1GLB1GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632833-B2 | Anticancer agents | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287414-A1 | Mitotic Kinesin Inhibitors | KIF5B, KIF2C, KIF18B | GUSB 2652/4885EBP 3342/4885SIGMAR1 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.